Acomplia (rimonabant) Nastech Pharmaceutical Company Inc. and Merck & Co., Inc. announced that they have entered into a global alliance to develop and commercialize Peptide YY 3-36 Nasal Spray (PYY), Nastech’s Phase I product for the treatment of obesity.
Under the agreement, Merck will assume primary responsibility for clinical and non--clinical studies and regulatory approval.
The investigational PYY3-36 Nasal Spray, currently in Phase I development, is designed to deliver the natural, appetite-regulating hormone PYY directly to the bloodstream. Nastech has completed three Phase I clinical trials, each designed to answer specific questions Acomplia (rimonabant) regarding safety, tolerability, dosing and scheduling.
Acomplia (rimonabant) “Nastech’s innovative research and development capabilities are reflected in its rapid advancement of PYY,” said Peter S. Kim, Ph.D., president of Merck Research Laboratories. “Our alliance with Nastech recognizes the potential of PYY as a possible treatment for obesity, a disease with significant unmet medical need.”
“ It is extremely encouraging to see groundbreaking research in obesity applied toward the development of potential treatments to target this epidemic,” said Barbara Corkey, Ph.D., president of the North American Association for the Study of Obesity, the nation’s leading scientific society dedicated to advancing research and treatment of obesity Acomplia (rimonabant) .
Peptide YY is a naturally occurring hormone that has been implicated as a physiologic inhibitor of food intake. PYY is produced by specialized endocrine cells (L-cells) in the gut after a person eats and is believed to trigger the feeling of satiety, or fullness. Because PYY is a protein, initial studies focused on PYY delivery by injection. Utilizing its proprietary drug delivery technology, Nastech developed the nasal spray formulation of PYY as a unique, non-invasive treatment option for obesity Acomplia (rimonabant) .
Метки:
clinical,
drug,
obesity,
study,
Zimulti
Посмотрите также
- Zimulti Acomplia News About Rimonabant Sales of Acomplia Lag, But Sanofi Still Has High Hopes for Rimonabant
With sales of Acomplia (rimonabant) lagging in the several dozen countries where it is on the market, Sanofi-Aventis executives had little to say about their pioneering obesity treatment in a report to analysts on Feb. 12th. But that hardly means they have given up on the CB-1 receptor antagonist. [...]
- Zimulti Acomplia News — Oct. 2007 — News About Rimonabant
Diet Drug Taranabant Yields Encouraging Results With ‘Generally Mild’ Side-Effects Taranabant, which a year from now may have surged past (Acomplia) rimonabant as the world’s most eagerly awaited diet drug, made a low-key debut Oct. 24th when researchers reported that participants in a clinical trial achieved encouraging weight loss with [...]
- Waiting for More Acomplia Trial Results
When two year results of the RIO-North America (Rimonabant In Obesity) trial were presented at the American Heart Association (AHA) scientific meeting in New Orleans in November, researchers said additional results from studies underway could be expected by the end of the year.
But seven weeks have passed with no news on [...]
- Study: Acomplia Weight Loss Modest and Side-Effects Are Concern
Professor Raj Padwal and colleagues found that Acomplia (rimonabant) resulted in a somewhat larger weight loss than Xenical or Meridia, but noted that adverse effects were recorded with all three drugs and in particular, with Acomplia (rimonabant).
“ The most worrying adverse effect was an increased incidence of psychiatric disorders (depression, anxiety, [...]
- Study: Acomplia Produces Weight Loss and Metabolic Improvement
Quebec City, Canada, March 9, 2004 - Results of a Phase III clinical trial (RIO-Lipids or Rimonabant In Obesity) comparing rimonabant, the first drug in a new Acomplia (rimonabant) class called Selective CB1 Blockers (or SCB1Bs), to placebo found that overweight or obese patients with untreated dyslipidemia (high triglycerides, low HDL-cholesterol) lost [...]
- Study: Acomplia Increases the Likelihood of Success in Quitting Smoking
Researchers at the University of Cincinnati Acomplia (rimonabant) College of Medicine presented results of one of the largest smoking cessation trials ever conducted in the United States, STRATUS-US (STudies with Rimonabant And Tobacco USe). The findings show that a new drug, rimonabant, doubled the odds of quitting smoking compared with placebo, markedly [...]
If you enjoyed this post, please consider to leave a comment or subscribe to the feed and get future articles delivered to your feed reader.
Comments
Еще нет комментариев.
Извините, комментирование на данный момент закрыто.